In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Santhera Pharmaceuticals Holding (SPHDF – Research Report), with a price target of CHF25.00.
Ram Selvaraju has given his Buy rating due to a combination of factors, including Santhera Pharmaceuticals’ recent agreement on the reimbursement level for vamorolone with the German National Association of Statutory Health Insurance Funds. This agreement marks a significant milestone as AGAMREE becomes the first product to secure a federal price for treating Duchenne muscular dystrophy in Germany, covering a substantial portion of the population. The reimbursement amount per patient exceeds initial expectations, highlighting the potential for increased market adoption and revenue generation.
Additionally, the commercialization efforts for vamorolone are progressing well, with expected submissions to Canadian authorities and ongoing negotiations in key European markets. These developments suggest a promising trajectory for market penetration across Europe in the coming years. Furthermore, the impending transition to a new Chief Financial Officer may bring fresh strategies to enhance financial operations, thereby supporting Santhera’s growth objectives. These elements collectively underpin the reiterated Buy rating and the 12-month price target of CHF25 per share.